GLP-1 Drugs Outperform Metformin in Prediabetes Study Presented at American Heart Association Meetings
Glucagon-like peptide-1 receptor agonists perform more effectively than metformin at treating prediabetes and lowering the risk of type 2 diabetes, heart attack, and stroke, according to research presented November 2, 2026, at the American Heart Association’s Scientific Sessions. The observational analysis examined electronic health records for 256,492 adults diagnosed with prediabetes and obesity, comparing patients prescribed GLP-1 medications against those taking metformin.
Participants taking medications such as semaglutide, tirzepatide, liraglutide, or dulaglutide demonstrated a 1.5 times higher likelihood of reversing high blood sugar to healthy levels compared to patients using metformin. Researchers also reported that GLP-1 users experienced a 31% lower risk of progressing to type 2 diabetes and a 41% lower risk of death from any cause over the study period. The data showed 15% fewer heart attacks, 20% fewer strokes, 25% fewer heart failure events, and 8% fewer cases of atrial fibrillation among GLP-1 recipients.
Clinical Perspectives on Treatment Options and Costs
Serra, a research fellow in the department of cardiovascular medicine at the Mayo Clinic in Scottsdale, Arizona, stated that the findings support considering GLP-1 therapies earlier for certain patients rather than waiting for type 2 diabetes to develop. However, Serra noted that metformin remains a first-line treatment choice that is safe, inexpensive, and has a long track record. David Cutler, a family medicine physician, called the results impressive.
Robert Eckel, a past volunteer president of the American Heart Association, emphasized that patient costs and medication access remain critical barriers. Eckel suggested that the observed benefits likely stem primarily from weight loss and noted that GLP-1 receptor agonists provide a viable alternative or add-on strategy for cardiovascular risk reduction in this population.
Observational data limits direct cause conclusions
Study authors cautioned that the research relies on electronic health records and observational data, meaning it cannot establish a direct cause-and-effect relationship. The review utilized prescription records without tracking exact patient adherence, dosages, or individual differences between specific GLP-1 agents, which were evaluated as a single category. According to statistics cited by the American Heart Association, approximately 115 million adults in the United States live with prediabetes, with up to 10% progressing to type 2 diabetes annually.
Weight loss drives cardiovascular risk reduction
Why do GLP-1 medications lower cardiovascular risks in prediabetes patients?
Researchers and independent specialists note that the cardiovascular benefits observed among GLP-1 users are likely driven largely by weight loss. Preventing the transition from prediabetes to type 2 diabetes also inherently reduces long-term risks for heart attacks and strokes.
How do the findings compare with previous clinical trials?
The results align with phase 3 clinical trials such as the STEP 10 trial published in 2024, which found that 81% of adults with obesity and prediabetes receiving weekly semaglutide reverted to normal blood glucose levels at 52 weeks compared to 14% on placebo.
What lifestyle modifications are recommended alongside medication?
Physicians emphasize that lifestyle interventions remain foundational, advising patients with prediabetes to lose weight, reduce dietary carbohydrates, and exercise daily before or alongside medication management.
Keep reading